170 related articles for article (PubMed ID: 31832930)
1. An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.
Shao S; Huang WC; Lin C; Hicar MD; LaBranche CC; Montefiori DC; Lovell JF
Ann Biomed Eng; 2020 Jul; 48(7):1991-2001. PubMed ID: 31832930
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
Matyas GR; Wieczorek L; Beck Z; Ochsenbauer-Jambor C; Kappes JC; Michael NL; Polonis VR; Alving CR
AIDS; 2009 Oct; 23(16):2069-77. PubMed ID: 19710597
[TBL] [Abstract][Full Text] [Related]
3. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
[TBL] [Abstract][Full Text] [Related]
4. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.
Huang WC; Deng B; Mabrouk MT; Seffouh A; Ortega J; Long C; Miura K; Wu Y; Lovell JF
Malar J; 2020 Aug; 19(1):309. PubMed ID: 32859199
[TBL] [Abstract][Full Text] [Related]
5. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
6. Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.
Hanson MC; Abraham W; Crespo MP; Chen SH; Liu H; Szeto GL; Kim M; Reinherz EL; Irvine DJ
Vaccine; 2015 Feb; 33(7):861-8. PubMed ID: 25559188
[TBL] [Abstract][Full Text] [Related]
7. Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.
Venditto VJ; Watson DS; Motion M; Montefiori D; Szoka FC
Clin Vaccine Immunol; 2013 Jan; 20(1):39-45. PubMed ID: 23114698
[TBL] [Abstract][Full Text] [Related]
8. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.
Lai RP; Hock M; Radzimanowski J; Tonks P; Hulsik DL; Effantin G; Seilly DJ; Dreja H; Kliche A; Wagner R; Barnett SW; Tumba N; Morris L; LaBranche CC; Montefiori DC; Seaman MS; Heeney JL; Weissenhorn W
J Biol Chem; 2014 Oct; 289(43):29912-26. PubMed ID: 25160627
[TBL] [Abstract][Full Text] [Related]
9. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.
Liu H; Su X; Si L; Lu L; Jiang S
Protein Cell; 2018 Jul; 9(7):596-615. PubMed ID: 29667004
[TBL] [Abstract][Full Text] [Related]
10. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
[TBL] [Abstract][Full Text] [Related]
11. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.
Serrano S; Araujo A; Apellániz B; Bryson S; Carravilla P; de la Arada I; Huarte N; Rujas E; Pai EF; Arrondo JLR; Domene C; Jiménez MA; Nieva JL
J Biol Chem; 2014 Mar; 289(10):6565-6580. PubMed ID: 24429284
[TBL] [Abstract][Full Text] [Related]
12. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
Huarte N; Araujo A; Arranz R; Lorizate M; Quendler H; Kunert R; Valpuesta JM; Nieva JL
PLoS One; 2012; 7(12):e52740. PubMed ID: 23285173
[TBL] [Abstract][Full Text] [Related]
13. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
14. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
[TBL] [Abstract][Full Text] [Related]
16. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
[TBL] [Abstract][Full Text] [Related]
17. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
Verkoczy L; Chen Y; Zhang J; Bouton-Verville H; Newman A; Lockwood B; Scearce RM; Montefiori DC; Dennison SM; Xia SM; Hwang KK; Liao HX; Alam SM; Haynes BF
J Immunol; 2013 Sep; 191(5):2538-50. PubMed ID: 23918977
[TBL] [Abstract][Full Text] [Related]
18. Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies.
Kim S; Filsinger Interrante MV; Kim PS
J Virol; 2023 Jan; 97(1):e0164722. PubMed ID: 36541800
[TBL] [Abstract][Full Text] [Related]
19. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
[TBL] [Abstract][Full Text] [Related]
20. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
Williams WB; Alam SM; Ofek G; Erdmann N; Montefiori DC; Seaman MS; Wagh K; Korber B; Edwards RJ; Mansouri K; Eaton A; Cain DW; Martin M; Hwang J; Arus-Altuz A; Lu X; Cai F; Jamieson N; Parks R; Barr M; Foulger A; Anasti K; Patel P; Sammour S; Parsons RJ; Huang X; Lindenberger J; Fetics S; Janowska K; Niyongabo A; Janus BM; Astavans A; Fox CB; Mohanty I; Evangelous T; Chen Y; Berry M; Kirshner H; Van Itallie E; Saunders KO; Wiehe K; Cohen KW; McElrath MJ; Corey L; Acharya P; Walsh SR; Baden LR; Haynes BF
Cell; 2024 Jun; 187(12):2919-2934.e20. PubMed ID: 38761800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
